Success Story

Carisma Therapeutics continues to grow

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies co-founded by Penn Medicine’s Saar Gill, MD, PhD, raised a Series B equity financing this year bringing the total amount raised in this round to $59 million and Carisma’s total capital raised to date to nearly $121 million. 

Dr. Gill is an Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and chair of the company’s scientific advisory board. 

This Series B round included additional funding from founding investors, IP Group, Inc. and Penn Medicine, and new investor 4BIO Capital. They join the initial Series B investor syndicate of SymBiosis II, Solasta Ventures, Livzon Pharmaceuticals Group, AbbVie Ventures, HealthCap, Wellington Partners, TPG Biotech, Agent Capital and MRL Ventures Fund.

Saar Gill
Saar Gill, MD, PhD
Skip to content